Development of a Novel, Single-Cycle Replicable Rift Valley Fever Vaccine
Figure 8
Protection efficacy of scMP-12.
Five-week-old CD1 mice were intramuscularly immunized with 104 PFU of MP-12, 105 PFU of MP-12, 105 PFU of scMP-12, and 105 PFU of VRP or with HBSS. Forty days after vaccination, immunized mice were challenged with 103 PFU of the wt ZH501 strain of RVFV (104 PFU of MP-12, n = 19; 105 PFU of MP-12, n = 10; 105 PFU of scMP-12, n = 29; 105 PFU of VRP, n = 9; and HBSS, N = 10). The mice were observed and survival recorded for 21 days after challenge.